A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

Maria Gonzalez; Alexander M. Menzies; Thomas E. Pennington; Robyn P.M. Saw; Andrew J. Spillane; Jonathan R. Stretch; Kerwin F. Shannon; Sydney Ch’ng; Omgo E. Nieweg; Maria Cruzado Rojas; Monica Osorio; Robert V. Rawson; Peter M. Ferguson; Helen Rizos; Serigne Lo; Richard A Scolyer; Georgina V. Long

doi:10.1200/jco.2020.38.15_suppl.tps10088

Abstract

2 min read

TPS10088 Background: Recent clinical trials of neoadjuvant (neo-adj) ipilimumab combined with nivolumab (OpACIN & OpACIN-neo) in resectable stage III melanoma show that a pathological response ( < 50% viable tumour at the tumour bed as determined by histopathological analysis) is associated with a prolonged relapse-free survival compared to no pathological response. Furthermore, recurrences seldom occur in those who have a pathological response following neo-adj immunotherapy with only 1/71 pts (1.4%) having recurred. In contrast, 15/23 (65.2%) pts with no pathological response have relapsed to date. The NeoPeLe trial will test the hypothesis that the synergistic combination of PD-1 blockade (pembrolizumab) with anti-angiogenic/multiple RTK inhibitor (lenvatinib) will result in a high rate of pathological response in the resected surgical specimen with a low rate of toxicity. Tissue and blood biomarkers are drawn at several timepoints and correlated to clinical and pathological endpoints to explore mechanisms of response and resistance. We will compare pathological response rate, and other clinical outcomes in this study, with previously published neo-adj clinical trials to select the best schedules for larger-scale clinical testing. Across neo-adj studies, we will also analyse the tissue collected to explore determinants of the optimal therapy for individual pts, whilst minimising toxicity. Methods: Eligible pts with stage IIIB/C/D, resectable and measurable (RECIST 1.1) nodal metastatic melanoma will be enrolled to this phase II single-centre trial (n = 20). All pts undergo complete nodal resection (RES) at wk 6 following neo-adj therapy with pembrolizumab (200mg, IV, 3 wkly) and lenvatinib (20mg, oral, daily). Adjuvant therapy with pembrolizumab is given for 46 wks after RES. After 52 wks of the study treatment, pts will be followed for relapse and survival for 5 years. CT and FDG PET/CT are used to measure response and exclude progression in the neo-adj phase, and to monitor for recurrence during adj and post treatment phases. Blood and tumour samples are collected at baseline, day 8, RES and at relapse if feasible. Faecal samples are collected at baseline and before RES. The primary endpoint is the complete pathological response rate at RES following 6 wks of neo-adj therapy. Secondary endpoints include RECIST response, metabolic response, OS, RFS, safety/tolerability, surgical outcomes, quality of life, and biomarker analyses. Clinical trial information: NCTNCT04207086.

Related publications

Article2016

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.

Robyn P.M. Saw, Alexander M. Menzies, Alexander Guminski, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Sydney Ch’ng, Richard Kefford, John F. Thompson, Jonathan R. Stretch, Andrew J. Spillane, Richard A Scolyer, Georgina V. Long

Article2019

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

Irene L. M. Reijers, Elisa A. Rozeman, Alexander M. Menzies, Bart A. van de Wiel, Hanna Eriksson, Karijn P.M. Suijkerbuijk, Astrid Aplonia Maria Van Der Veldt, Ellen Kapiteijn, Geke A.P. Hospers, W. Martin C. Klop, Andrew J. Spillane, Richard A Scolyer, Inge Marie Svane, Lars Bastholt, Henrik Schmidt, James Larkin, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank

Article2024

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

Maria Gonzalez, Alexander Christopher Jonathan Van Akkooi, Sydney Ch’ng, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, Michael Rtshiladze, Thomas E. Pennington, David J. Coker, Robyn P.M. Saw, Rony Kapoor, Edward Hsiao, Robert V. Rawson, Monica Osorio, Alexander M. Menzies, Serigne Lo, Richard A Scolyer, Angela Hong, Georgina V. Long, Ines Esteves Domingues Pires Da Silva

Article2024

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long

Article2023

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.

Maria Gonzalez, Alexander Christopher Jonathan Van Akkooi, Andrew J. Spillane, Sydney Ch’ng, Kerwin F. Shannon, Jonathan R. Stretch, Michael Rtshiladze, Thomas E. Pennington, Robyn P.M. Saw, Alexander M. Menzies, Robert V. Rawson, Linda K. Martin, Pascale Guitera, Mary Jane Gregorio, Kevin London, Rony Kapoor, Edward Hsiao, Serigne Lo, Richard A Scolyer, Georgina V. Long